Alice H. Berger

Alice H. Berger

Auto-generated profile, based on publicly available information

Alice H. Berger

Department of Genome Sciences, University of Washington, Seattle, WA, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 January 2020 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
JTJames D. Thomas
James D. Thomas
JPJacob T. Polaski
Jacob T. Polaski
QFQing Feng
Qing Feng
ENEmma J. De Neef
Emma J. De Neef
EHEmma R. Hoppe
Emma R. Hoppe
RBRobert K. Bradley
Robert K. Bradley

1 August 2021 in Cell Reports
Verified
Journal Article
Open access
PPPhoebe C.R. Parrish
Phoebe C.R. Parrish
JTJames D. Thomas
James D. Thomas
AGAustin M. Gabel
Austin M. Gabel
SKShriya Kamlapurkar
Shriya Kamlapurkar
RBRobert K. Bradley
Robert K. Bradley
ABAlice H. Berger
Alice H. Berger
CRISPR screens have accelerated the discovery of important cancer vulnerabilities. However, single-gene knockout phenotypes can be masked by redundancy among related genes. Paralogs constitute two-thirds of the human protein-coding genome, so existing methods are likely inadequate for assaying a large portion of gene function. Here, we develop paired guide RNAs for paralog genetic interaction mapping (pgPEN), a pooled CRISPR-Cas9 single- and double-knockout approach targeting more than 2,000 human paralogs. We apply pgPEN to two cell types and discover that 12% of human paralogs exhibit synthetic lethality in at least one context. We recover known synthetic lethal paralogs MEK1/MEK2, important drug targets CDK4/CDK6, and other synthetic lethal pairs including CCNL1/CCNL2. Additionally, we identify ten tumor suppressor paralog pairs whose compound loss promotes cell proliferation. These findings nominate drug targets and suggest that paralog genetic interactions could shape the landscape of positive and negative selection in cancer.

20 January 2022 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
OUOana Ursu
Oana Ursu
JNJames T. Neal
James T. Neal
ESEmily Shea
Emily Shea
PTPratiksha I. Thakore
Pratiksha I. Thakore
LJLivnat Jerby
Livnat Jerby
JBJesse S. Boehm
Jesse S. Boehm

9 August 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
AVAthea Vichas
Athea Vichas
ARAmanda K. Riley
Amanda K. Riley
NNNaomi T. Nkinsi
Naomi T. Nkinsi
SKShriya Kamlapurkar
Shriya Kamlapurkar
PPPhoebe C. R. Parrish
Phoebe C. R. Parrish
ABAlice H. Berger
Alice H. Berger
CRISPR-based cancer dependency maps are accelerating advances in cancer precision medicine, but adequate functional maps are limited to the most common oncogenes. To identify opportunities for therapeutic intervention in other rarer subsets of cancer, we investigate the oncogene-specific dependencies conferred by the lung cancer oncogene, RIT1. Here, genome-wide CRISPR screening in KRAS, EGFR, and RIT1-mutant isogenic lung cancer cells identifies shared and unique vulnerabilities of each oncogene. Combining this genetic data with small-molecule sensitivity profiling, we identify a unique vulnerability of RIT1-mutant cells to loss of spindle assembly checkpoint regulators. Oncogenic RIT1M90I weakens the spindle assembly checkpoint and perturbs mitotic timing, resulting in sensitivity to Aurora A inhibition. In addition, we observe synergy between mutant RIT1 and activation of YAP1 in multiple models and frequent nuclear overexpression of YAP1 in human primary RIT1-mutant lung tumors. These results provide a genome-wide atlas of oncogenic RIT1 functional interactions and identify components of the RAS pathway, spindle assembly checkpoint, and Hippo/YAP1 network as candidate therapeutic targets in RIT1-mutant lung cancer.

1 February 2021 in Cell Reports
Verified
Journal Article
Open access
JCJian Carrot-Zhang
Jian Carrot-Zhang
XYXiaotong Yao
Xiaotong Yao
SDSiddhartha Devarakonda
Siddhartha Devarakonda
ADAditya Deshpande
Aditya Deshpande
JDJeffrey Damrauer
Jeffrey Damrauer
MIMarcin Imielinski
Marcin Imielinski
RTK/RAS/RAF pathway alterations (RPAs) are a hallmark of lung adenocarcinoma (LUAD). In this study, we use whole-genome sequencing (WGS) of 85 cases found to be RPA(-) by previous studies from The Cancer Genome Atlas (TCGA) to characterize the minority of LUADs lacking apparent alterations in this pathway. We show that WGS analysis uncovers RPA(+) in 28 (33%) of the 85 samples. Among the remaining 57 cases, we observe focal deletions targeting the promoter or transcription start site of STK11 (n = 7) or KEAP1 (n = 3), and promoter mutations associated with the increased expression of ILF2 (n = 6). We also identify complex structural variations associated with high-level copy number amplifications. Moreover, an enrichment of focal deletions is found in TP53 mutant cases. Our results indicate that RPA(-) cases demonstrate tumor suppressor deletions and genome instability, but lack unique or recurrent genetic lesions compensating for the lack of RPAs. Larger WGS studies of RPA(-) cases are required to understand this important LUAD subset.

25 July 2024 in JCI Insight
Verified
Journal Article
Open access
PDF file
SMSitapriya Moorthi
Sitapriya Moorthi
APAmy Paguirigan
Amy Paguirigan
PIPushpa Itagi
Pushpa Itagi
MKMinjeong Ko
Minjeong Ko
MPMary Pettinger
Mary Pettinger
ABAlice H. Berger
Alice H. Berger
Over 200,000 individuals are diagnosed with lung cancer in the United States every year, with a growing proportion of cases, especially lung adenocarcinoma, occurring in individuals who have never smoked. Women over the age of 50 comprise the largest affected demographic. To understand the genomic drivers of lung adenocarcinoma and therapeutic response in this population, we performed whole genome and/or whole exome sequencing on 73 matched lung tumor/normal pairs from postmenopausal women who participated in the Women’s Health Initiative. Somatic copy number alterations showed little variation by smoking status, suggesting that aneuploidy may be a general characteristic of lung cancer regardless of smoke exposure. Similarly, clock-like and APOBEC mutation signatures were prevalent but did not differ in tumors from smokers and never-smokers. However, mutations in both EGFR and KRAS showed unique allelic differences determined by smoking status that are known to alter tumor response to targeted therapy. Mutations in the MYC-network member MGA were more prevalent in tumors from smokers. Fusion events in ALK , RET , and ROS1 were absent, likely due to age-related differences in fusion prevalence. Our work underscores the profound effect of smoking status, age, and sex on the tumor mutational landscape and identifies areas of unmet medical need.